Loading
Latest filing published 12 Jan 2022 for Caladrius Biosciences, INC.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
This profile gathers the share dealings of Steven S. Myers in Lisata Therapeutics, Inc. Over a trading history stretching from 25 January 2016 to 10 January 2022, the count stands at 3 filings.
Purchases make up the whole of the open-market record (1 purchase, €27k). A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 2 share grants.
The newest entry dates from 12 January 2022: a share grant, in Lisata Therapeutics, Inc. The last insider purchase was made public on 10 December 2021, 1,774 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations